A 28-year-old woman from rural Maharashtra presents with fatigue, dyspnea on exertion, and menorrhagia for the past 8 months. On examination, she is pale with conjunctival pallor and tachycardia (HR 102/min). Laboratory findings: Hemoglobin 7.2 g/dL, MCV 62 fL, serum ferritin 12 ng/mL, serum iron 35 µg/dL, TIBC 420 µg/dL, transferrin saturation 8%. Peripheral blood smear shows microcytic hypochromic RBCs with occasional target cells. What is the most appropriate next step in management?

Explanation

## Diagnosis and Clinical Context **Key Point:** This patient has iron deficiency anemia (IDA) with clear evidence of iron depletion—low ferritin, low serum iron, elevated TIBC, and low transferrin saturation. ### Diagnostic Confirmation | Finding | Value | Interpretation | |---------|-------|----------------| | Hemoglobin | 7.2 g/dL | Moderate anemia | | MCV | 62 fL | Microcytic (< 80 fL) | | Ferritin | 12 ng/mL | Depleted iron stores (< 30 ng/mL = IDA) | | TIBC | 420 µg/dL | Elevated (normal 250–425) | | Transferrin saturation | 8% | Severely reduced (< 16% = IDA) | | Peripheral smear | Microcytic hypochromic | Consistent with IDA | **High-Yield:** In IDA, ferritin < 30 ng/mL is virtually diagnostic; TIBC elevation and low transferrin saturation confirm absent iron stores. ### Management Algorithm ```mermaid flowchart TD A[Confirmed IDA]:::outcome --> B{Hemoglobin < 7 g/dL?}:::decision B -->|Yes| C[Transfusion if symptomatic/unstable]:::action B -->|No| D[Oral iron first-line]:::action D --> E[Ferrous salt 100-200 mg elemental Fe daily]:::action E --> F[Investigate cause: menorrhagia, GI bleed, etc.]:::action F --> G[Recheck Hb in 4-6 weeks]:::action G --> H{Hb rise > 1 g/dL?}:::decision H -->|Yes| I[Continue iron, address underlying cause]:::action H -->|No| J[Check compliance, malabsorption, ongoing loss]:::decision J -->|Persistent failure| K[Consider IV iron or parenteral therapy]:::action ``` ### Why Oral Iron Is First-Line Here 1. **Hemoglobin 7.2 g/dL:** Patient is symptomatic but hemodynamically compensated (HR 102 is tachycardia, not shock). No acute decompensation requiring transfusion. 2. **Oral ferrous sulfate 200 mg daily:** Provides ~60 mg elemental iron; standard dosing for IDA. Absorption improves on empty stomach; vitamin C enhances uptake. 3. **Investigate menorrhagia:** Heavy menstrual bleeding is the most common cause of IDA in reproductive-age women in India. Gynecological evaluation (pelvic ultrasound, CBC, coagulation screen) is essential. 4. **Expected response:** Hb should rise 1–2 g/dL over 4–6 weeks if compliance is good and iron stores are repleted. **Clinical Pearl:** Oral iron is preferred over IV in uncomplicated IDA because it is safer, cheaper, and equally effective when malabsorption is excluded. IV iron is reserved for intolerance, non-compliance, ongoing blood loss exceeding oral replacement capacity, or severe anemia requiring rapid correction. **Warning:** Do NOT transfuse a patient with Hb 7.2 g/dL unless there is acute bleeding, cardiac instability, or neurological symptoms. Over-transfusion increases iron overload risk and delays diagnosis of the underlying cause. ## Why Thalassemia Trait Is Not the Diagnosis **Key Point:** Thalassemia trait (β-thalassemia minor) presents with microcytic anemia BUT normal or elevated ferritin and normal TIBC. This patient's iron studies are diagnostic of depletion, not thalassemia. - **Target cells on smear:** Present in both IDA and thalassemia, but ferritin and TIBC differentiate them. - **Bone marrow biopsy:** Unnecessary and invasive for IDA diagnosis; reserved for unclear cases or suspected bone marrow pathology.